Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AC176 in Chinese Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05673109 is registered in ClinicalTrials.gov with Accutar Biotechnology Inc as lead sponsor.

NCT NCT05673109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05673109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AC176 in Chinese Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Accutar Biotechnology Inc
Phase
Phase 1
Overall status
Terminated
Start date
February 22, 2023
Completion date
October 8, 2023
Enrollment
8 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer